|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 13, 2016 ) Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights:
The report Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Small-Cell Lung Cancer (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 10, 7, 12 and 2 respectively for Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively for Small-Cell Lung Cancer.
Small-Cell Lung Cancer (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university
sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/small-cell-lung-cancer-pipeline-review-h2-2016
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001492627/sample
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Companies profiles
4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc
Alchemia Ltd
Amgen Inc
Andarix Pharmaceuticals Inc
Aposense Ltd
Aprea AB
Astellas Pharma Inc
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bayer AG
BeiGene Ltd
Beta Pharma Inc
BioLineRx Ltd
Bionomics Ltd
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corp
CellAct Pharma GmbH
Cellceutix Corp
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001492627/discount
List of Table
Small-Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 100
Small-Cell Lung Cancer - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 101
Small-Cell Lung Cancer - Pipeline by Sunshine Biopharma Inc, H2 2016 102
Small-Cell Lung Cancer - Pipeline by Syros Pharmaceuticals Inc, H2 2016 103
Small-Cell Lung Cancer - Pipeline by Tarveda Therapeutics Inc, H2 2016 104
Small-Cell Lung Cancer - Pipeline by Tesaro Inc, H2 2016 105
Small-Cell Lung Cancer - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 106
Small-Cell Lung Cancer - Pipeline by Verastem Inc, H2 2016 107
Small-Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Inc, H2 2016 108
Small-Cell Lung Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2016 109
Assessment by Monotherapy Products, H2 2016 110
Assessment by Combination Products, H2 2016 111
Number of Products by Stage and Target, H2 2016 113
Number of Products by Stage and Mechanism of Action, H2 2016 120
Number of Products by Stage and Route of Administration, H2 2016 127
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
